Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
J. Hou
ORCID:
0009-0004-9541-7569
Observed ORCID:
0009-0004-9541-7569
OpenAlex ID:
A5086412230
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
2022
·
M.R. Mirza
, X. Wu
, et al.
·
Annals of Oncology
·
10
35O Overall survival of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer adjusted for subsequent PARPi use in placebo group: Results from an ad hoc interim analysis for the phase III NORA study
2023
·
X. Wu
, J. Zhu
, et al.
·
ESMO Open
·
1
PDF
Show more works
View as search
Works count:
2
Citation count:
11
H-index:
1
I10-index:
1
Year
Topic
Type